OBJECTIVES: To evaluate the capacity of serum from carriers of LCAT gene mutations to promote cell cholesterol efflux through the ABCA1, ABCG1, and SR-BI pathways. METHODS: Serum was obtained from 41 carriers of mutant LCAT alleles (14 carriers of two mutant LCAT alleles and 27 heterozygotes) and 10 non-carrier relatives (controls). The capacity of serum to promote cholesterol efflux was tested in pathway-specific cell models. RESULTS: LCAT deficient sera were significantly more efficient than control sera in promoting cell cholesterol efflux via ABCA1 (3.1+/-0.3% for carriers of two mutant LCAT alleles and 2.6+/-0.2% for heterozygotes vs. 1.5+/-0.4% for controls), and less efficient in promoting ABCG1- and SR-BI-mediated cholesterol efflux. The enhanced capacity of LCAT deficient serum for ABCA1 efflux is explained by the increased content of prebeta-HDL, as indicated by the significant positive correlation between ABCA1 efflux and serum prebeta-HDL content (R=0.468, P<0.001). Moreover, chymase treatment of LCAT deficient serum selectively degraded prebeta-HDL and completely abolished ABCA1 efflux. Despite the remarkable reductions in serum HDL levels, LCAT deficient sera were as effective as control sera in removing mass cholesterol from cholesterol-loaded macrophages. CONCLUSIONS: Serum from carriers of LCAT gene mutations has the same capacity of control serum to decrease the cholesterol content of cholesterol-loaded macrophages due to a greater cholesterol efflux capacity via ABCA1.
OBJECTIVES: To evaluate the capacity of serum from carriers of LCAT gene mutations to promote cell cholesterol efflux through the ABCA1, ABCG1, and SR-BI pathways. METHODS: Serum was obtained from 41 carriers of mutant LCAT alleles (14 carriers of two mutant LCAT alleles and 27 heterozygotes) and 10 non-carrier relatives (controls). The capacity of serum to promote cholesterol efflux was tested in pathway-specific cell models. RESULTS: LCAT deficient sera were significantly more efficient than control sera in promoting cell cholesterol efflux via ABCA1 (3.1+/-0.3% for carriers of two mutant LCAT alleles and 2.6+/-0.2% for heterozygotes vs. 1.5+/-0.4% for controls), and less efficient in promoting ABCG1- and SR-BI-mediated cholesterol efflux. The enhanced capacity of LCAT deficient serum for ABCA1 efflux is explained by the increased content of prebeta-HDL, as indicated by the significant positive correlation between ABCA1 efflux and serum prebeta-HDL content (R=0.468, P<0.001). Moreover, chymase treatment of LCAT deficient serum selectively degraded prebeta-HDL and completely abolished ABCA1 efflux. Despite the remarkable reductions in serum HDL levels, LCAT deficient sera were as effective as control sera in removing mass cholesterol from cholesterol-loaded macrophages. CONCLUSIONS: Serum from carriers of LCAT gene mutations has the same capacity of control serum to decrease the cholesterol content of cholesterol-loaded macrophages due to a greater cholesterol efflux capacity via ABCA1.
Authors: Sophie Stukas; Lita Freeman; Michael Lee; Anna Wilkinson; Alice Ossoli; Boris Vaisman; Stephen Demosky; Jeniffer Chan; Veronica Hirsch-Reinshagen; Alan T Remaley; Cheryl L Wellington Journal: J Lipid Res Date: 2014-06-20 Impact factor: 5.922
Authors: I Zanotti; C Maugeais; M Pedrelli; M Gomaraschi; P Salgam; L Calabresi; F Bernini; H Kempen Journal: Br J Pharmacol Date: 2011-11 Impact factor: 8.739
Authors: M P Adorni; F Zimetti; M Puntoni; F Bigazzi; F Sbrana; F Minichilli; F Bernini; N Ronda; E Favari; T Sampietro Journal: J Lipid Res Date: 2012-03-12 Impact factor: 5.922
Authors: Xavier Rousset; Boris Vaisman; Bruce Auerbach; Brian R Krause; Reyn Homan; John Stonik; Gyorgy Csako; Robert Shamburek; Alan T Remaley Journal: J Pharmacol Exp Ther Date: 2010-07-06 Impact factor: 4.030